ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 10.62B 9.31B 8.58B 7.93B 15.03B 1,013B 15.28B 102B 40.2B 499B 39.88B 39.01B 1,717B | P/E 2026 * |
-17.8x | P/E 2027 * | -36.9x |
|---|---|---|---|---|---|
| Enterprise Value | 10.37B 9.08B 8.38B 7.74B 14.67B 989B 14.92B 100B 39.25B 487B 38.93B 38.08B 1,676B | EV / Sales 2026 * |
11.7x | EV / Sales 2027 * | 7.46x |
| Free-Float |
99.09% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 2012-06-30 |
Brett Monia
CEO | Chief Executive Officer | 64 | 2019-12-31 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 2000-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 2005-12-12 |
| Director/Board Member | 73 | 2002-04-30 | |
Brett Monia
BRD | Director/Board Member | 64 | 2019-03-24 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 10.62B | |
| +0.58% | +2.06% | +2.92% | +10.86% | 50.44B | |
| -2.22% | -1.25% | +385.40% | +586.81% | 40.63B | |
| -0.54% | +0.39% | +25.57% | -5.28% | 34.88B | |
| -1.36% | +0.35% | +17.88% | +55.14% | 33.67B | |
| +1.21% | -4.58% | +3.00% | +35.46% | 26.29B | |
| -1.81% | -1.48% | - | - | 17.11B | |
| +0.51% | -3.47% | +63.97% | +122.60% | 15.29B | |
| +0.23% | -0.58% | +13.76% | +21.11% | 13.74B | |
| -0.62% | -3.09% | +10.29% | -31.35% | 12.93B | |
| Average | -0.27% | -0.01% | +65.35% | +99.42% | 27.22B | |
| Weighted average by Cap. | -0.42% | +0.77% | +81.98% | +126.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 889M 779M 718M 664M 1.26B 84.8B 1.28B 8.58B 3.37B 41.77B 3.34B 3.27B 144B | 1.41B 1.24B 1.14B 1.05B 2B 135B 2.03B 13.63B 5.35B 66.38B 5.3B 5.19B 228B |
| Net income | -594M -520M -480M -443M -841M -56.64B -855M -5.73B -2.25B -27.9B -2.23B -2.18B -96.02B | -292M -256M -236M -218M -413M -27.83B -420M -2.82B -1.1B -13.71B -1.1B -1.07B -47.18B |
| Net Debt | -252M -221M -204M -188M -357M -24.08B -363M -2.44B -956M -11.86B -948M -927M -40.82B | -86.16M -75.48M -69.6M -64.31M -122M -8.22B -124M -831M -326M -4.05B -323M -316M -13.93B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
